Abstract:Background: We aimed to develop and validate a radiomics signature based on pretreatment MRI images to predict a good response (GR) to neoadjuvant chemotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) and to research its prognostic value in predicting distant metastasis.Methods: A total of 922 patients with LARC were retrospectively recruited from 3 Chinese hospitals between Dec 1, 2009, and Jan 30, 2018. The training dataset was comprised of 509 patients from centre I; external validation dataset 1 (EVD1) was comprised of 242 patients from centre II; and EVD2 was comprised of 171 patients from centre III. The radiomics features were extracted from the T2WI and ADC images. A three-step procedure, including the least absolute shrinkage and selection operator (LASSO) algorithm, minority oversampling technique (SMOTE) and support vector machine (SVM) classifier, was applied for feature selection and signature building. The prediction performance was evaluated using the area under the curve (AUC), accuracy, sensitivity and specificity. A nomogram integrating the radiomics signature and clinical-MRI features to predict distant metastasis (DM) was constructed.Findings: Nineteen, 3, and 22 radiomic features were selected in the T2WI-based, ADC-based, and fusion models for GR prediction, respectively. Among the three models, the fusion model showed satisfactory discrimination of GR to nCRT and yielded AUCs of 0.89±0.02 (95% CI, 0.87−0.92), 0.69±0.05 (95% CI, 0.61−0.78), and 0.72±0.04 (95% CI, 0.65−0.79) in the training and two external validation datasets, respectively. In addition, the combined nomogram was successfully built with AUCs of 0.69, 0.78 and 0.66 in the three datasets. Kaplan‒Meier curves of disease-free survival(DFS) between the high-risk and low-risk DM patients who were grouped by the nomogram showed statisticalsignificance with p<0.05 in the three datasets.Interpretation:The MRI-based radiomics signature exhibited promising performance for response prediction to nCRT in LARC patients and can also provide prognostic value for DM prediction, which may assist in individualized clinical treatment.Funding Information: This study was supported by the National Natural Science Foundation of China (No. 82001776, 81971687, 82271946), Shanghai AntiCancer Association Young Eagle Program (SACA-CY20C130),Shanghai Natural Science Foundation (No. 20ZR1412700). Declaration of Interests: All authors declare no competing interests. Ethics Approval Statement: This retrospective multicentre study was conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from the Institutional Review Board of all participating centres, and the requirement for informed consent was waived due to the retrospective nature. A total of 509 consecutive patients with LARC were enrolled in Fudan University Shanghai Cancer Center (FUSCC) from 2016/05 to 2018/01; 171 consecutive patients from 2013/03 to 2016/11 were enrolled in Shanxi Cancer Hospital (SXPCH); and 242 consecutive patients from 2009/12 to 2015/05 were enrolled in Beijing Cancer Hospital (BJCH).

Radiomics-Based Pretherapeutic Prediction of Non-response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Machine learning for prediction of chemoradiation therapy response in rectal cancer using pre-treatment and mid-radiation multi-parametric MRI

Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI.

Radiomics Model Based on Intratumoral and Peritumoral Features for Predicting Major Pathological Response in Non-Small Cell Lung Cancer Receiving Neoadjuvant Immunochemotherapy

Multi-parametric MRI radiomics for predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer

Radiopathomics Integrated Artificial Intelligence Predict Neoadjuvant Treatment Response for Locally Advanced Rectal Cancer: A Multicentre, Retrospective, Cohort Study

Radiomics Signature Based on Support Vector Machines for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial.

MRI-Based Radiomics Predicts Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Predicting pathological complete response by comparing MRI-based radiomics pre- and postneoadjuvant radiotherapy for locally advanced rectal cancer

MRI-based Radiomics to Predict Neoadjuvant Chemoradiotherapy Outcomes in Locally Advanced Rectal Cancer: A Multicenter Study

Prediction of pathological response and lymph node metastasis after neoadjuvant therapy in rectal cancer through tumor and mesorectal MRI radiomic features

Radiomic Features Are Predictive of Response in Rectal Cancer Undergoing Therapy

Magnetic resonance imaging-based radiomics analysis for prediction of treatment response to neoadjuvant chemoradiotherapy and clinical outcome in patients with locally advanced rectal cancer: A large multicentric and validated study

MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer

Mri-Based Radiomics Signature for Predicting Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Rectal Cancer: A Multicentre Study

MRI-Based Radiomic Models Outperform Radiologists in Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

A multiple-time-scale comparative study for the added value of magnetic resonance imaging-based radiomics in predicting pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Machine learning-based multiparametric MRI radiomics for predicting poor responders after neoadjuvant chemoradiotherapy in rectal Cancer patients